Forced Degradation Study and Development of a Stability-Indicating Method for Amoxicillin Capsules According to ANVISA Guidelines

Margareth B. C. Gallo, a,*, Diogo D. do Nascimento,b Nelson M. Nunes,b Flávia F. M. de Sousa,b Janine Boniatti,a José L. N. de Aguiar,a Juliana J. S. Medeiros,b Alessandra L. Esteves,b Graça M. S. Guerra,a,b Luiz E. M. Ferreira,b Lucas G. I. Regis,b Rafael C. Seiceira,b Fabiana M. S. U. Moncorvo,b and Marcelo H. C. Chavesb

aDepartamento de Saúde e Ambiente, Fundação Oswaldo Cruz (Fiocruz Ceará), 61760-000 Eusébio-CE, Brazil
bInstituto de Tecnologia em Fármacos (Farmanguinhos), Fiocruz, 21040-900 Rio de Janeiro-RJ, Brazil

This study aimed to develop a reliable stability-indicating method (SIM) for amoxicillin 500 mg capsules (DP-drug product). A literature review addressing amoxicillin (AMX; DS-drug substance) forced degradation studies and the existing SIMs was conducted to verify the most significant outcomes. Subsequently, the forced degradation of DP and DS was carried out following the Brazilian Health Surveillance Agency (ANVISA) guidelines, including thermal degradation (dry and wet heat), acidic and alkaline hydrolyses, hydrogen peroxide oxidation, reaction with copper, and photodegradation. Both DS and DP were more susceptible to 0.015 M NaOH, resulting in approximately 50% degradation. AMX DS and DP were not significantly photodegraded, but some degradation products (PDegs) showed susceptibility to light exposure. Thermodegraded samples showing ≥ 10% degradation exhibited modified profiles in thermogravimetric (TG) and differential scanning calorimetric (DSC) analyses. The X-ray powder diffraction patterns (XRPD) of DS samples exposed to dry and wet heat displayed complete amorphization of AMX, attesting to the occurrence of physical degradation concomitantly with chemical degradation, which can alter the drug’s bioavailability. In contrast, the thermodegraded DP samples exhibited intact AMX crystals interspersed with the amorphous form, perhaps partly protected by the excipient. The validated SIM was able to detect and quantify about 80 PDegs.

Keywords: thermogravimetry, differential scanning calorimetry, X-ray powder diffraction, method validation, stress testing

Introduction

Amoxicillin (AMX) is an aminopenicillin antibiotic used worldwide in clinical chemotherapy that contains a highly strained β-lactam amide bond with pronounced susceptibility to several nucleophiles, acidic and alkaline reagents, metal ions, oxidizing agents, and even solvents such as water and alcohols. Concerns about AMX stability and patient safety prompted researchers to investigate AMX degradation products (PDegs) and methods capable of detecting and quantifying them, a subject that was extensively reviewed by Deshpande et al.1 and de Marco et al.2 Initially, microbiological assays were used to determine the strength of AMX, but they had the inconvenience of not being accurate or not being able to monitor low levels of PDegs and impurities.3 High-performance liquid chromatography has emerged as an efficient method to determine AMX and its synthetic impurities, p-hydroxyphenylglycine (p-HPG; related substance I; RS I) and 6-aminopenicillanic acid (RS A), and hydrolysis PDegs (amoxicillin penicilloic/penilloic acid epimers: RS D1/D2 and RS E1/E2, respectively) in biological fluids and dosage forms.4,5 Breakthroughs in analytical techniques have provided the means to improve the resolution, detection and characterization of AMX PDegs (Table S1, Supplementary Information (SI) section).6-10 Meanwhile, several norms on stability study and impurity control have been established by international health surveillance agencies for both DS and DP, requiring a comparison between these rules to harmonize the approach with which studies of forced degradation of drugs and development of stability-indicating methods (SIMs) should be performed.11 Even so, countless results of AMX
degradation studies published in the literature lack details that allow its reproducibility or were not performed considering all the recommended reactions, as mentioned in Table 1, raising numerous doubts about which procedure should be followed.

Currently, only a few pharmacopoeias, e.g., British Pharmacopoeia\textsuperscript{19} and Japanese Pharmacopoeia,\textsuperscript{20} have methods for assaying AMX and its related substances (RS) in capsules, but only the limit for individual impurities has been established. In this context, our research group started the development of a formulation for generic amoxicillin 500 mg capsules using amoxicillin trihydrate produced by sustainable enzymatic synthesis.\textsuperscript{21}

This work describes the forced degradation study of AMX DS and DP and the development and validation of a SIM, in line with the guidelines of the Brazilian Health Surveillance Agency (ANVISA), capable of detecting and quantifying about 80 PDegs. Moreover, thermogravimetric (TG), differential scanning calorimetric (DSC) and X-ray powder diffraction patterns (XRPD) analyses of the degraded samples were carried out in order to better understand the impact of AMX degradation on drug product (DP).

**Experimental**

**Chemical reagents**

Amoxicillin trihydrate, batch No. 1611503389 (assay: 99.2\% AMX; 0.06\% RS A; 0.02\% RS I; 0.02\% RS D1; 0.09\% RS D2; 0.01\% RS E2; 0.17\% RS J; 0.01\% RS G; 0.06\% unknown impurities; 0.46\% total impurities), was purchased from Aurobindo Pharma (Hyderabad, India). Amoxicillin 500 mg capsules, batches No. 1502EX018-2 (submitted to stability study) and No. 1609EX116 (submitted to forced degradation studies and method validation), was manufactured by Farmanguinhos (Rio de Janeiro, Brazil).

**SIM development**

A Lachrom Elite high performance liquid chromatography (HPLC) system (Merck, Darmstadt, Germany) with a photodiode array detector was used to develop and validate the SIM according to the data in Table S2 (SI section).

**SIM validation**

The optimized HPLC method was validated according to ANVISA guidelines.\textsuperscript{22,23} The maximum reported limit (MRL) for each RS from amoxicillin 500 mg capsules was 1\%, according to the British Pharmacopoeia,\textsuperscript{19} and the Japanese Pharmacopoeia.\textsuperscript{20} Statistical analyses were performed according to Bazílio \textit{et al.}'\textsuperscript{24} The concentration levels, corresponding to anhydrous AMX, used to determine linearity in SIM and assay method ranged from the limit of quantitation to 120\% of the MRL (0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 µg mL\textsuperscript{-1}) and from 80 to 120\% (400, 450, 500, 550 and 600 µg mL\textsuperscript{-1}) working concentration, respectively.

**X-ray powder diffraction analysis**

XRPD patterns were obtained using a X-ray diffractometer (model D8-Advance, Bruker, Karlsruhe, Germany) operated at 40 kV and 40 mA, using Cu K\textalpha\textsubscript{1} radiation (\(\lambda\ K\alpha_1 = 1.54060 \text{ Å}; \lambda\ K\alpha_2 = 1.54438 \text{ Å}\)). Each sample was scanned from 3 to 50° (2\(\theta\)) at 0.2° per second, which is the allowable tolerance on diffraction angle to establish identity. Crystallographic data for amoxicillin trihydrate were found in the Cambridge Structural Database.\textsuperscript{25}

**Differential scanning calorimetry and thermogravimetry**

DSC graphics were recorded on a calorimeter (model 822/700 DS, Mettler Toledo, Ohio, USA) under a dynamic nitrogen atmosphere at a flow rate of 80 mL min\textsuperscript{-1}, scan range of 25-200 °C, and heating rate of 10 K min\textsuperscript{-1}. Samples weighing 3.0 to 7.0 mg were placed in 40-100 µL aluminum crucibles, which were subsequently sealed with aluminum lids and drilled with a pin at the time of the experiments. The equipment was calibrated with indium and zinc (not less than 99.99\%) for temperature and enthalpy.

Simultaneous TG was performed in a TG analyzer (model 851/LF1100, Mettler Toledo, Ohio, USA) under a dynamic nitrogen atmosphere at a flow rate of 50 mL min\textsuperscript{-1}, scan range of 25-200 °C, and heating rate of 10 °C min\textsuperscript{-1}. Samples weighing 23.5 to 25.0 mg were placed in covered 150 µL aluminum crucibles. The module was calibrated with aluminum and indium (not less than 99.99\%) for temperature. All samples were analyzed in duplicate.

**Stress testing**

Amoxicillin trihydrate, amoxicillin 500 mg capsules, and the respective placebo (magnesium stearate) were subjected to forced degradation reactions in accordance with ANVISA guidelines.\textsuperscript{26,27} The reactions were carried out using amounts corresponding to 1.25 mg mL\textsuperscript{-1} of anhydrous AMX in diluent 2 (0.01 M KH\textsubscript{2}PO\textsubscript{4} buffer pH 5/
Table 1. State of the art of amoxicillin forced degradation study

| Stress testing | Nagle and Monte et al. | Raju et al. | Tippa and Singh | Pérez-Patricia et al. | Beg et al. | Fritschi et al. | Konat and Jacob | Bucarci et al. | Atici et al. |
|----------------|------------------------|-------------|----------------|-----------------------|------------|----------------|----------------|----------------|-------------|
| AH             | 12.5 mg mL⁻¹ AMX in DMSO, 0.05 M HCl, 25 °C, 1 h | 0.75 mg mL⁻¹ AMX in 0.05 M phosphate buffer pH 5, 1 M HCl, 25 °C, 30 min | 0.2 mg mL⁻¹ AMX in water, 0.5 M HCl, 25 °C, 2 h | 0.5 µg mL⁻¹ AMX in fomic acid pH 2, 5 days | 5 µg mL⁻¹ AMX in MeOH/002 M phosphate buffer pH 3/5, 0.50.5:1/v/v, 0.5 M HCl under reflux, 70 °C, 2 h | 85.7 µg mL⁻¹ AMX in diethyl (not mentioned), 0.014 M HCl under reflux, 60-70 °C, 90 min | 2 mg mL⁻¹ AMX in 0.01 M HCl, MeOH/002M, pH 5 | 105.375.6:1.65, v/v/v , 0.1 M HCl, 25 °C, 4 h | 0.5 mg mL⁻¹ AMX in water, 0.5 M HCl, 25 °C, 7 min |
| degradation / % | NI | 9.5 | 7 | residues of AMX | 20-25 | NI | 26 | 6 | 0.5 mg mL⁻¹ AMX in water, 50 °C, 5 min |
| detected RS    | C, D, E1, E2, G | D1, D2, C1, D1 | E1, E2 | NI | 1 unknown | 2 unknowns | D, 5 unknowns | 5 | |
| NH or Me       | NP | 13.12 | 13.12 | NI | 7 | NI | none | 7 | |
| BH             | 0.75 mg mL⁻¹ AMX in 0.05 M phosphate buffer pH 5, 0.5 M NaOH (time and temperature were not informed) | 0.2 mg mL⁻¹ AMX in water, 0.1 M NaOH, instantly | 0.5 µg mL⁻¹ AMX in NH₄OH pH 0:24 h | 5 µg mL⁻¹ AMX in MeOH/002 M phosphate buffer pH 3/5, 0.50.5:1/v/v, 0.025 M NaOH under reflux, 70 °C, 2 h | AMX in aqueous KOH pH 10 heated for a few hours | 85.7 µg mL⁻¹ AMX in 0.014 M NaOH under reflux, 60-70 °C, 90 min | 2 mg mL⁻¹ AMX in 0.01 M HCl, MeOH/002M, pH 5 | MeOH/03.75:6.15, v/v/v, 0.1 M NaOH, 25 °C, 7 days | 0.5 mg mL⁻¹ AMX in water, 0.1 M NaOH, 25 °C, 20 min |
| degradation / % | NI | 9.5 | 6.21 | complete degradation | 15-20 | NI | NI | none | 7 |
| detected RS    | C2, D1, D2, J, H, N-pivaloyl amoxicillin | C1, C2 | NI | D | 1 unknown | none | C, D, G, J, 2 unknowns | 3 | |
| HP             | 0.75 mg mL⁻¹ AMX in 0.05 M phosphate buffer pH 5, 0.5 M NaOH (time and temperature were not informed) | 0.2 mg mL⁻¹ AMX in water, 0.1 M NaOH, instantly | 0.5 µg mL⁻¹ AMX in NH₄OH pH 0:24 h | 5 µg mL⁻¹ AMX in MeOH/002 M phosphate buffer pH 3/5, 0.50.5:1/v/v, 0.025 M NaOH under reflux, 70 °C, 2 h | AMX in aqueous KOH pH 10 heated for a few hours | 85.7 µg mL⁻¹ AMX in 0.014 M NaOH under reflux, 60-70 °C, 90 min | 2 mg mL⁻¹ AMX in 0.01 M HCl, MeOH/002M, pH 5 | MeOH/03.75:6.15, v/v/v, 0.1 M NaOH, 25 °C, 7 days | 0.5 mg mL⁻¹ AMX in water, 0.05 M NaOH, 25 °C, 10 min |
| degradation / % | NI | 10.8 | 5.0 | complete degradation | 15-20 | NI | NI | none | 7 |
| detected RS    | A, B, D1, D2, C, | A, B, D1, D2, E1, G1, L, N-pivaloyl amoxicillin | C1, C2 | NI | D | 1 unknown | none | C, D, J, 6 unknowns | 3 |
| DT             | 105 °C, 3 h | 105 °C, 3 h | 20 °C | 105 °C | 20 °C, 2 h | 105 °C, 3 h | 20 °C | 105 °C, 7 days | none | 3 |
| degradation / % | NP | 14 | NI | none | 7 | NP | none | B, C, D, H, 4 unknowns | 7 |
| detected RS    | A, B, C2, D1, D2, E1, G1, L, N-pivaloyl amoxicillin | NP | NP | NP | NP | NP | NP | NP |
| WT             | 92% RH, 25 °C, 144 h | 92% RH, 25 °C, 144 h | 105 °C, 144 h | 105 °C, 144 h | 6 mL of 0.1 mg mL⁻¹ AMX in volumetric flask, 60-70 °C, hot air oven, 90 min | 6 mL of 0.1 mg mL⁻¹ AMX in volumetric flask, 60-70 °C, hot air oven, 90 min | 6 mL of 0.1 mg mL⁻¹ AMX in petri dish, photostability chamber: 3 days, 200 W h per m², 25 °C, 26 days | UV light, 3 days | UV light, 3 days, 200 W h per m², 25 °C, 26 days |
| PhD            | 1.2 million bx h, 144 h (temperature was not mentioned) | 0.2 mg mL⁻¹ AMX in water, UV light, 3 h | 15 µg mL⁻¹ AMX in MeOH/002 M phosphate buffer pH 3/5, 1:1/v/v, 1.2 million bx h, 25 °C, 144 h, and UV light, 254 nm, 3 h | 6 mL of 0.1 mg mL⁻¹ AMX in petri dish, photostability chamber: 1.2 million bx h, 200 W h per m², 25 °C, 26 days | UV light, 3 days | 7 and 4, respectively | 7 and 4, respectively | 7 and 4, respectively |
| degradation / % | NP | 0.1 | 8.59 | 5 and 7, respectively | NP | NP | NP | NP |
| detected RS    | C2, D1, 1 | C2, D1, 1 | 1 | C2, D1, 1 | 1 | C2, D1, 1 | 1 | C2, D1, 1 | 1 |

AMX: amoxicillin; FLUC: flucloxacillin; ENROFLOX: enrofloxacin; CLAV: potassium clavulinate; LC/ESI-MS: liquid chromatography coupled to mass spectrometer with electrospray source; SIM: stability-indicating method; ESMS: mass spectrometer with electrospray source; DS: drug substance; DP: drug product; NI: not informed; NP: not performed; PDegs: degradation products; AH: acid hydrolysis; NH: neutral hydrolysis; Me: methanolation; BH: alkaline hydrolysis; HP: hydrogen peroxide oxidation; DT: dry heat degradation; WT: wet heat degradation; PhD: photodegradation; A, B, C, D, E, F, G, H, I, K, L: related substances of amoxicillin and its isomers (numbered) according to the European Pharmacopoeia; RS: related substances; MeOH: methanol; MeCN: acetonitrile; RH: relative humidity; UV: ultraviolet; DMSO: dimethyl sulfoxide; bx: bx hour.
methanol 8:2 v/v) or as a thin layer of powder inside glass flasks as follows: thermodegradation in dry hot air oven at 105 °C for 3 h; thermodegradation in pre-saturated hot air oven with steam at 105 °C for 3 h; photodegradation under 1.2 million-lux hours and 200 watts h per m² at 25 °C for 17 days, in a photostability chamber in which an actinometric chemical system validated using 2% quinine monohydrochloride dihydrate guaranteed exposure to light, as the difference in absorbance was ≥ 0.5 AU; acid hydrolysis in 0.375 M HCl at 25 °C for 30 min; alkaline hydrolysis in 0.015 M NaOH at 25 °C for 15 min; oxidative degradation in 1.5% H₂O₂ at 25 °C for 30 min; reaction with 0.001 M copper(II) acetate solution in water pH 3 at 25 °C, in the absence of light, for 30 min. Acidic and alkaline hydrolyses were neutralized with NaOH and HCl solutions, respectively. 0.1 M ethylenediaminetetraacetic acid (EDTA) was used to quench Cu²⁺-catalyzed degradation. Each sample was diluted to approximately 0.5 mg mL⁻¹ AMX and injected in duplicate, except for the peroxide degradation samples, which were injected only once immediately after the end of the time allotted for the reaction, as it was not quenched, as well as blank (diluent) and control (reaction medium). The chromatogram of each degraded sample (DS, DP, and placebo) was compared with the chromatograms of the blank, a non-degraded sample (reference) and the control. Peaks that occurred only in degraded samples and/or that appeared in a greater proportion than in the reference sample were considered PDEgs.

Stability studies were conducted under a long-term condition (30 °C, 75% relative humidity, 24 months), and samples were analyzed according to the SIM reported herein.

Results and Discussion

SIM development

Several methods have been described in the literature or pharmacopoeias for assaying AMX and its PDEgs in the drug substances and formulated products (Tables 1, 2 and S2). Most of these methods are based on liquid chromatography coupled with an ultraviolet detector, using C18 columns and gradient elution employing phosphate or acetate buffers, pH 2-6, methanol, acetonitrile or a mixture as mobile phases. As our laboratory was already using the United States Pharmacopoeia method (method 1; SI section, Table S2) to assay AMX DS impurities, it seemed practical to continue using it for DP. However, when a system suitability solution containing AMX and some PDEgs (SI section, “Stability-indicating method (SIM) development” sub-section) was injected, despite the very good parameters observed in the chromatogram, the method proved inadequate for the analysis of RSs because many peaks were observed in the first 3 min, including RS I, D1, D2, A, and AMX (Figure 1a). Therefore, any other degradation product formed could overlap the RS peaks whose retention times dropped in the first few minutes of running. The SIM used by the manufacturer to assay AMX DS impurities (method 2, Table S2, SI section) showed a very good resolution across all peaks (Figure 1b), but a prohibited duration of 60 min for an analytic method used in process control. Method 3 was based on method 2, but lasted 20 min less (Table S2, SI section). However, the high concentration of buffer damaged the column after 90 injections, preventing validation from being completed. Method 4, using ammonium acetate buffer, was very effective and could be validated as a liquid chromatography-mass spectrometry method (Table S2, SI section), but was not robust when transferred to the production area laboratory, exhibiting baseline oscillation for each gradient change, especially around the RS J retention time. This problem could be solved by increasing the buffer concentration to 0.01 M and extending the run time by using 75% mobile phase A for an additional five minutes. This alternative was tried with phosphate buffer instead of acetate buffer, giving method 5 (Figure 1c; Table S2, SI section), which exhibited good baseline stability using a lower buffer concentration and had a 15 min shorter run time than method 2. The monitoring wavelength was 210 nm, based on the maximum absorptions exhibited by the components of the system suitability solution 1 (SI section, “Stability-indicating method (SIM) development” sub-section). Degradation reactions were analyzed using method 5, and no PDEgs were detected at retention times > 35 min, therefore the method duration was reduced to 40 min and the validated SIM (method 5 optimized) was described in Table 2.

Forced degradation profile

When the results of AMX forced degradation were collected from the literature and analyzed, they seemed somewhat controversial regarding the percentage of degradation and the products yielded. Knowing the influence of some reagents and solvents on AMX and its related substances, we decided to test some diluents during the degradation study. First, AMX was dissolved in 0.05 M KH₂PO₄ buffer pH 5 (named Dil1), following the manufacturer’s and the US Pharmacopeia methods (methods 1 and 2, respectively, Table S2, SI section). The degradation reactions were carried out under various conditions to achieve degradation rates between 10 and 30%, as suggested by the regulatory agency (Table 3,
degradation reaction in Dil1). It took approximately 1 h for AMX to completely dissolve. Related substance J was produced as a diluent artifact in a range of up to 6.0% in the reference solutions of AMX DS and DP, which was far beyond the MRL and the 0.17% determined by the manufacturer in the AMX DS, perhaps due to the increase in temperature in the ultrasound bath. Next, we tested solutions containing 10, 20 and 30% methanol in 0.01 M KH₂PO₄ buffer pH 5, controlling the temperature of the ultrasound bath through the occasional addition of ice to keep it below 30 °C. The results were comparable to those reported by Felix et al., and the dissolution time decreased with increasing alcohol concentration. The greater the concentration of methanol, the greater the formation of amoxicilloic acid methyl ester (RS P), however, in a percentage range well below that observed for RS J using only buffer as the diluent. In the reference solutions prepared with buffer containing 20% methanol (named Dil2), the percentage area of RS P ranged from 0.13 to 0.25%, while RS J ranged from 0.25 to 0.33%. For this reason, the degradation reactions were carried out again using Dil2 under optimized conditions to obtain the desired degradation range (Table 3, degradation reaction in Dil2). All degraded samples showed percentage area for

| Method | Mobile phase | Gradient | Column | Flow / (mL min⁻¹) | IV / µL | CO/AutoS / °C | Detector / nm | Sample solution | Requirements |
|--------|--------------|----------|--------|------------------|--------|--------------|---------------|----------------|--------------|
|        | A: 0.01 M KH₂PO₄ pH 5.0 | 0-2 | 99.5 | ACE C8 | 150 x 4.6 mm, 5 µm particle size, 100 Å pore size, 300 m² g⁻¹ superficial area, 9% carbon load | 1.0 | 10 | 40/4 | 210 | inject | 0.5 mg mL⁻¹ AMX in mobile phase A/MeOH 8:2 v/v, ultrasound for 20 min with ice to keep temperature below 30 °C (AMX is stable for 8 h at 25 °C, for 72 h at 4 °C; RS I, D1, and P for 4 h at both temperatures) |
| Method 5 optimized | MeCN/MeOH 96:4 v/v | 6 | 98 | 14 | 96 | 16 | 88 | 26 | 86 | 35 | 75 | 35.1-40 | 99.5 |

Table 2. Assay and stability-indicating method developed and validated for AMX 500 mg capsules

| Method | Mobile phase | Gradient | Column | Flow / (mL min⁻¹) | IV / µL | CO/AutoS / °C | Detector / nm | Sample solution | Requirements |
|--------|--------------|----------|--------|------------------|--------|--------------|---------------|----------------|--------------|
| British | A: 0.05 M KH₂PO₄ pH 5/MeCN 99:1 v/v | 0-AMX tᵦ | 92 | Hypersil C18 | 250 x 4.6 mm, 5 µm, 120 Å, 10% carbon load | 1 | 50 | rt | 254 | resolution between internal standard (cefadroxil) and AMX NLT 1, AMX LMT 2, individual impurities NMT 1% |
| | B: buffer/MeCN 80:20 v/v | 25 | 0 | 40 | 0 | 40.1-55 | 92 | |

Japanese | CH₃CO₂Na pH 4.5/MeOH 95:5 v/v | run time 32 min | adjusted for AMX tᵦ in 8 min | 10 | 25/rt | 254 | AMX theoretical plates NLT 2500, symmetry factor NMT 1.5, individual impurities NMT 1% |

The most relevant stability-indicating method reported in literature for AMX capsules

| Method | Mobile phase | Gradient | Column | Flow / (mL min⁻¹) | IV / µL | CO/AutoS / °C | Detector / nm | Sample solution | Requirements |
|--------|--------------|----------|--------|------------------|--------|--------------|---------------|----------------|--------------|
| Fong et al. | A: 0.05 M KH₂PO₄ pH 5.9 | 0-5 | 100 | 2 Spherisorb C18 columns connected in series: 150 x 4.6 mm, 5 µm, 80 Å, 11.5% carbon load | 1 | 50 | rt | 220 | 1.0 mg mL⁻¹ AMX in water, ultrasound for 30 min with ice to keep temperature below 30 °C (stable for 3 h at room temperature) |
| | B: MeOH/MeCN 3:1 v/v | 25 | 60 | 30 | 60 | 35 | 100 | 50 | 100 | tᵦ of RS D1/D2, I and A between 1-12 min, RSD NMT 15% |

IV: injection volume; CO: column oven temperature; AutoS: autosampler temperature; MeOH: methanol; MeCN: acetonitrile; AMX: amoxicillin; tᵦ: retention time; RS: related substance; rt: room temperature; NLT: not less than; NMT: no more than; RSD: relative standard deviation.
Forced Degradation Study and Development of a Stability-Indicating Method for Amoxicillin Capsules

RS P similar to the reference solutions, ranging from 0.05 to 0.25%, except for samples degraded by copper(II), acid or alkali, which showed an average of 0.7, 4.3 and 35%, respectively. The formation of RS J was observed in large proportion in the dry and wet thermodegraded samples (mean of 2.5 and 10%, respectively), as expected, and much less in the copper catalyzed hydrolysis (1%). All other degraded samples showed percentage areas (0.04 to 0.19%) similar to the reference solutions. Considering all the pros and cons, 20% methanol in phosphate buffer pH 5 was chosen as the best diluent as it reduced the AMX dissolution time for approximately 20 min. In addition, the origin of RS P could be explained as coming exclusively from the diluent, while if there was an increase in the RS J, its origin could not be distinguished between diluent artifact or thermal degradation product, with a false increase in impurity that could disqualify the entire batch. About 80 PDegs were determined (Table S6, SI section) and mass balance was achieved (98.3-100.0%) throughout the forced degradation study. Thermal degradation reactions displayed the release of a characteristic sulfur smell, which corroborates the carbonyl sulfide formation observed by Gálico et al., using thermogravimetry coupled to Fourier transform infrared spectroscopy.

The placebo did not degrade under any of the conditions tested. AMX DS and DP showed similar degradation profiles (Figures 2 and 3), forming the largest number of PDegs during dry and wet thermal degradation (Table S6, SI section). However, the profiles obtained in the hydrolysis reactions were more dependent on the diluent used than on the concentration of the reagents or the method used. In Dil1, copper(II), alkali or acid catalyzed hydrolysis yielded RS D2 as the main degradation product, and in Dil2 it formed RS P, C and D2 (Figure 2).

Figure 1. Chromatograms of the system suitability solution obtained using method 1 (a), method 2 (b), and method 5 (c). The system suitability solution contained the related substances I, D1, D2, A, G, E1, E2, C, F, J, P and amoxicillin (AMX).
Table 3. Results of the forced degradation study of amoxicillin drug substance and drug product

| Degradation reaction (in diluent 1) | Degraded DS / % | Degraded DP / % |
|------------------------------------|-----------------|-----------------|
| AH 0.55 M HCl, 20 min, rt         | 22.6            | 16.4            |
| BH 1.5 M NaOH, 15 min, rt         | 95.9            | 99.3            |
| BH 0.15 M NaOH, 30 s, rt          | 31.6            | 26.5            |
| Ox 15% H$_2$O$_2$, 20 min, 60 °C  | 98.5            | NC              |
| Ox 15% H$_2$O$_2$, 20 min, rt     | 65.7            | NC              |
| Ox 1% H$_2$O$_2$, 10 min, rt      | 7.2             | NC              |
| Ox 1% H$_2$O$_2$, 30 min, rt      | 15.8            | 15.4            |
| DT 60 °C, 5 h                     | 0.0             | NC              |
| DT 105 °C, 15 h                   | 45.8            | 25.3            |
| DT 105 °C, 1 h                    | 8.7             | 9.4             |
| WT 105 °C, 4.5 h                  | 36.0            | 34.7            |
| COP 6 mM Cu(OAc)$_2$, 25 min, rt  | 87.2            | NP              |
| COP 6 mM Cu(OAc)$_2$, 2 min, rt   | 35.2            | NP              |
| COP 1 mM Cu(OAc)$_2$, 15 min, rt  | 16.3            | 13.5            |

Degradation reaction (in diluent 2)

| AH 0.375 M HCl, 30 min, rt        | 15.8            | 14.1            |
| BH 0.015 M NaOH, 15 min, rt       | 51.2            | 47.9            |
| Ox 1% H$_2$O$_2$, 30 min, rt      | 12.1            | 12.6            |
| DT 105 °C, 3 h                    | 10.9            | 8.7             |
| WT 105 °C, 3 h                    | 27.8            | 22.3            |
| PhD 1.2 million lux h, 200 watts h m$^{-2}$, 25 °C | DS: 2.6         | DP: 3.8         |
|                                   | 17 days         | CAL: 0.8        | CAL: 1.6        |
| COP 1 mM Cu(OAc)$_2$, 30 min, rt  | 21.7            | 21.9            |

DS: amoxicillin trihydrate (AMX), drug substance; DP: amoxicillin 500 mg capsule, drug product; AH: acidic hydrolysis; BH: alkaline hydrolysis; Ox: hydrogen peroxide oxidation; DT: dry thermodegradation; WT: wet thermodegradation; PhD: photodegradation; COP: reaction with copper(II) acetate; rt: room temperature; CAL: control for absence of light; NP: not performed; Cu(OAc)$_2$: copper II acetate. Diluent 1: 0.05 M phosphate buffer pH 5. Diluent 2: 20% methanol in 0.01 M phosphate buffer pH 5 v/v. The AH, BH, Ox and COP reactions were carried out in amber flasks to avoid the influence of light. CAL was carried out in Petri plates wrapped in aluminum foil.

AMX DS, DP and placebo samples exposed to dry and wet heat and photodegradation were subjected to TG, DSC and XRPD analyses in order to investigate whether the extent of degradation was only chemical, or if there were any physical changes in AMX DS and DP. The DSC and TG curves of the reference DS agreed with those obtained by Gádio et al.34 The DSC profile of the reference DP was comparable to that of the reference DS and exhibited an endothermic event between 90 and 150 °C related to the dehydration of the molecule and, soon after, an exothermic event related to the degradation of AMX (Figure S3c, red and orange curves). The TG curve of the reference DP (Figure S4c, red and orange curves) showed a characteristic mass loss of 12.9% between 30 and 150 °C associated with dehydration of the molecule. The photodegraded samples showed no difference in the DSC and TG curves or in the XRPD patterns. However, the DS and DP thermodegraded samples showed profound changes in both curves (Figures S3 and S4, SI section), corroborating a total transformation of the DS crystal structure, resulting in the amorphization of DS, as revealed by the XRPD patterns (Figure S5b, SI section). Some authors argue that the amorphization of AMX occurs due to dehydration,35 while others claim that dehydrated AMX retains some crystallinity and reverts to trihydrate form upon absorbing water vapor,28 which could explain why the amorphous degraded DS samples lost a proportion of water similar to the reference samples (Figure S4, SI section). In contrast, the dry thermodegraded DP samples exhibited intact amoxicillin crystals interspersed with the amorphous form, perhaps partly protected by the excipient (Figure S5c, SI section, orange and green curves).

SIM and assay method validation

Carmo et al.36 reported the most common reasons for ANVISA to refuse licensing of DP, and many of them were linked to the development and validation of analytical methods. Due to this, all validation steps were followed according to ANVISA guidelines,22,23 considering linearity, range, selectivity, accuracy, precision, limit of quantitation (LOQ), limit of detection (LOD), and robustness.

System suitability

During the development of the method, the resolution between RSs A, D1/D2 and AMX, as well as between RSs C and P, proved to be a critical point to indicate the good performance of the column and of the system in general. Furthermore, the use of methanol in the mobile phase and in the diluent may favor the appearance of RS P, a fact that must be verified when reporting RSs. Therefore, the system suitability (SS) should always be evaluated with the SS solution 2 and the SS solution 3 and/or 4 (“System suitability” sub-section, Figure S1, SI section), depending on whether the assay method or the SIM was applied, respectively, before the injection of the DP sample.

Selectivity and specificity

The maximum peak purity value (1.0) obtained for AMX and its various PDegs via photodiode array in all degradation reactions proved that the method was able to resolve the PDegs and AMX very well (Table S6, SI section). In addition, no peak overlap was observed in the diluent or placebo chromatograms on AMX retention time.

Linearity and range

Calibration curves were constructed by plotting the peak area against the concentration. Data were analyzed using
Figure 2. Alkaline hydrolysis chromatograms of the DS using diluent 1 obtained by method 3 ((a) reference DS; (b) degraded DS at 0.15 M NaOH, 30 s), and using diluent 2 obtained by method 5 ((c) reference DS; (d) degraded DS at 0.015 M NaOH, 15 min).

Figure 3. Chromatograms of the drug product (DP) forced degradation study using diluent 2 obtained by method 5 ((a) reference DP; (b) acidic hydrolysis; (c) alkaline hydrolysis; (d) thermal degradation (dry heat); (e) photodegradation; (f) control of absence of light for photodegradation; (g) thermal degradation (wet heat); (h) hydrogen peroxide oxidation; (i) reaction with copper(II) acetate).
least squares linear regression. The values obtained for the coefficient of determination ($R^2$) in both curves (Figure 4) and the results of the statistical analyses (Table S3, SI section) showed a strong linear relationship between the variables $x$ (concentration) and $y$ (area) and homogeneity of variance of experimental errors for different observations.

**Limit of detection and limit of quantitation**

Initially, the LOD and LOQ were determined based on the intercept and slope values of the SIM curve as 0.139 and 0.417 µg mL$^{-1}$, respectively. Solutions with different concentrations were prepared and injected to obtain the empirical values (SI section, “Determination of limit of detection (LOD) and limit of quantitation (LOQ)” sub-section) determined as 0.1 µg mL$^{-1}$ (coefficient of variation (CV) = 2.5%) for LOD, and 0.3 µg mL$^{-1}$ (CV = 2.7%) and accuracy of 100.4% for LOQ.

**Determination of relative response factor (RRF) and relative retention time (RtR)**

RRF of AMX related substances A (0.525), G (0.336), C (0.1246) and F (1.461) were determined as described in the SI section (“Determination of relative response factor (RRF) of related substances” sub-section), and the RRF of any other related substances was considered equal to one. RtR was calculated as the ratio between the respective measurement for each RS and AMX (SI section, “Determination of relative retention time (RtR) of related substances” sub-section).

**Precision (intra- and inter-day) and accuracy**

Both the assay method and the SIM showed satisfactory precision and accuracy considering the analyses of the curve performed in solvent or the negligible matrix effect displayed (Table S4, SI section).

**Robustness**

Throughout the development of the method, it became evident that small changes in the chemical composition of the mobile phase, pH, or flow would enormously influence the method resolution, causing peak displacement or overlapping due to the large number of PDeGs and the zwitterionic nature of AMX, making it difficult even to identify the peaks through RtR. Therefore, these parameters must be kept constant. Only the variation in column oven temperature (40 ± 2 °C) did not significantly affect the precision and accuracy of the method (Table S5, SI section).

Filtering samples with nylon or regenerated cellulose membranes with a pore size of 0.45 µm did not alter the chromatographic responses of AMX DS and DP or RSs (SI section, “Determination of influence of filtration” sub-section).

The solution stability study (SI section, “Determination of stability of solutions” sub-section) revealed that AMX DS and DP solutions in Dil2 remained stable for about 8 h at 25 °C and for 72 h at 4 °C. However, RS I, D1 and P lasted approximately 4 h at both temperatures, with degradation increasing over time due to hydrolysis. For this reason, once the solutions are prepared, analysis should not last any longer.

**Challenging of the SIM**

A DP sample from long-term stability study at the six-month stage was used to challenge the SIM. The chromatographic profile showed about 30 peaks (SI section, Table S7 and Figure S2), which were also observed in the 45% thermodegraded DS sample (Table S6, SI section), corroborating the importance of this research in the prediction of PDeGs and the efficiency of the method in fulfilling the purpose for which it was developed.

![Figure 4](image-url) Figure 4. Calibration curves and residual plots from the assay (a, b) and from the stability-indicating method (c, d).
Conclusions

The degradation profile showed that AMX was prone to all reactions, but mainly to thermal degradation and hydrolysis. For this reason, there must be deliberate control of heat and humidity throughout the manufacturing, transport and storage process of the AMX DS and DP. The increase in the amount of amorphous AMX observed in thermodegraded DP samples makes the product more susceptible to hydrolysis, in addition to altering its bioavailability.

Amoxicillin DS and DP were susceptible to copper(II) and practically non-reactive to light (Figures 3i and 3e, respectively), but some related substances had their content decreased during photodegradation, requiring a careful choice of packaging, which should be light-proof and free of transition metals.

The presence of RS D1/D2 as one of the PDegs resulting from the reaction between AMX and copper(II) indicates that copper plays a catalyst role in the hydrolysis of the β-lactam ring, corroborating the results reported by Chen et al. However, RS C was the PDeg formed in the largest amount (Figure 3i), which points to a free radical-mediated auto-oxidation of AMX, in which there is an intramolecular attack on the β-lactam ring by the amino group in the benzyl position, with copper acting as an electron donor for molecular oxygen. This hypothesis could explain why the reaction extended for 24 h, even with the addition of 0.1 M EDTA as a reaction quencher, and the rate of degradation of AMX increased to 80%. The occurrence of similar parallel mechanisms could also explain the contradictory results found in the literature on the degradation rates of AMX, in addition to the influence of the diluent and the concentration of AMX in the reaction.

In a forced degradation study, the percentage degradation range of 10-30%, suggested in the literature, is not always sufficient to reveal all possible PDegs that may occur during a stability study. In the case of AMX, only a sample of DS thermodegraded at 105 °C for 15 h (Table S6, SI section), which presented a degradation rate of 45%, formed sufficient amount and number of PDegs whose peaks could be superimposed on the peaks detected in the sample submitted to the long-term stability study, highlighting the importance of obtaining higher degradation ranges than those recommended in reactions in which the drug is more susceptible.

Throughout the development of the SIM, we realized that there is no 100% optimal condition, so we chose the least degrading one for AMX. The use of methanol in the diluent, in addition to being cheaper and less toxic than acetonitrile, reduced the analysis time when compared to other methods, which represents savings in the quality control laboratory and in the final price of the product.

The validated SIM was able to selectively detect and quantify AMX and all impurities present in a DP sample submitted to a long-term stability study.

Supplementary Information

Supplementary information (extra sections, tables and figures mentioned in the main text) is available free of charge at http://jbcs.sbq.org.br as PDF file.

Acknowledgments

The authors would like to thank Farmanguinhos, Manoel Miqueias Maia for his help in making the graphical abstract, and the reviewers for their excellent comments and suggestions, which made this work even better.

Author Contributions

Margareth B. C. Gallo, Diogo D. do Nascimento, Nelson M. Nunes, Juliana J. S. Medeiros, Janine Boniatti, Fabiana M. S. U. Moncorvo and Marcelo H. C. Chaves were responsible for conceptualization, methodology and data curation; Margareth B. C. Gallo for validation, investigation, visualization, writing original draft, reviewing and editing; José L. N. de Aguiar, Alessandra L. Esteves and Graça M. S. Guerra for project administration and funding; Flávia F. F. de Sousa and Luiz E. M. Ferreira for validation; Lucas G. I. Regis and Rafael Seixeira for investigation and data curation.

References

1. Deshpande, A. D.; Baheti, K. G.; Chatterjee, N. R.;Curr. Sci. 2004, 87, 1684.
2. de Marco, B. A.; Natori, J. S. H.; Fanelli, S.; Tótoli, E. G.; Salgado, H. R. N.;Crit. Rev. Anal. Chem. 2017, 47, 267.
3. Hsu, M.; Hsu, P.;Antimicrob. Agents Chemother. 1992, 36, 1276.
4. Lee, T. L.; D’Arconte, L.; Brooks, M. A.; J. Pharm. Sci. 1979, 68, 454.
5. Fong, G. W. K.; Martin, D. T.; Johnson, R. N.; Kho, B. T.; J. Chromatogr. 1984, 298, 459.
6. Nägele, E.; Moritz, R.; J. Am. Soc. Mass Spectrom. 2005, 16, 1670.
7. Pérez-Parada, A.; Agüera, A.; Gomez-Ramos, M. M.; Garcíareyes, J. F.; Heinzen, H.; Fernandez-Alba, A. R.;Rapid Commun. Mass Spectrom. 2011, 25, 731.
8. Trovó, A. G.; Nogueira, R. F. P.; Agüera, A.; Fernandez-Alba, A. R.;Water Res. 2011, 45, 1394.
9. Gozlan, I.; Rotstein, A.; Avisar, D.; *Chemosphere* **2013**, *91*, 985.

10. Atici, E. B.; Yazar, Y.; Ağtaş, Ç.; Rıdvanoglu, N.; Karlıga, B.; *J. Pharm. Biomed. Anal.* **2017**, *136*, 1.

11. Susanowo, H. J.; *Forced Degradation Studies - Comparison Between ICH, EMA, FDA and WHO Guidelines and ANVISA’s Resolution RDC 53/2015*; MSc Dissertation, University of Bonn, Germany, 2016, available at https://dgra.de/media/pdf/studium/masterthesis/master_janzen_h.pdf, accessed in July 2021.

12. Raju, B. V. N.; Sharma, H. K.; Rao, S.; Rao, G. N.; *Acta Chromatogr.* **2009**, *21*, 57.

13. Tippa, D. M. R.; Singh, N.; *Am. J. Anal. Chem.* **2010**, *1*, 95.

14. Beg, S.; Hasnain, M. S.; Swain, S.; Kohli, K.; *Int. J. Pharm. Sci. Nanotechnol.* **2011**, *4*, 1423.

15. Frański, R.; Czerniel, J.; Kowalsk, M.; Frańksa, M.; *Rapid Commun. Mass Spectrom.* **2014**, *28*, 713.

16. Konari, S. N.; Jacob, J. T.; *J. Taibah Univ. Sci.* **2015**, *9*, 167.

17. Batrawi, N.; Wahdan, S.; Al-Rimawi, F.; *Sci. Pharm.* **2017**, *85*, 6.

18. The European Pharmacopoeia, 10th ed.; Council of Europe/ European Directorate for the Quality of Medicines and Healthcare (EDQM): London, 2018.

19. The British Pharmacopoeia, The British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare Products (MHRA): London, 2018.

20. The Japanese Pharmacopoeia, 17th ed., Pharmaceutical and Medical Devices Agency (PMDA): Tokyo, 2016.

21. Alemzadeh, I.; Borgehi, G.; Vafi, L.; Roostaaazad, S.; *Sci. Iran., Trans. C* **2010**, *17*, 106.

22. Agência Nacional de Vigilância Sanitária (ANVISA); Resolução da Diretoria Colegiada (RDC) No. 166, de 24 de julho de 2017, Diário Oficial da União (DOU), Brasília, No. 141, de 25/07/2017, p. 87, available at https://www.in.gov.br/materia/-/asset_publisher/Kujrw0TZC2Mb/content/id/19194581/d1-2017-07-25-resolucao-rdc-n-166-de-24-de-julho-de-2017-19194412, accessed in July 2021.

23. Agência Nacional de Vigilância Sanitária (ANVISA); *Guia para Tratamento Estatístico da Validação Analítica*, Guia No. 10, available at https://www.farmacuteicas.com.br/wp-content/uploads/2017/09/Guia-10-v1-Tratamento-estatistico-validacao-analitica.pdf, accessed in July 2021.

24. Bazfílo, F. S.; Bomfim, M. V. J.; Almeida, R. J.; Abrantes, S. M. P.; *Rev. Analítica* **2012**, *59*, 60.

25. Cambridge Structural Database (CSD), https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=AMOXCT10&DatabaseToSearch=PUBLISHED, accessed in July 2021.

26. Agência Nacional de Vigilância Sanitária (ANVISA); Resolução da Diretoria Colegiada (RDC) No. 53, *Estabelece Parâmetros para a Notificação, Identificação e Qualificação de Produtos de Degradação em Medicamentos com Substâncias Ativas Sintéticas e Semissintéticas, Classificados como Novos, Genéricos e Semilíquidos*, Dá Outras Providências, 2015, Diário Oficial da União (DOU), Brasília, No. 234, de 08/12/2015, available at http://antigo.anvisa.gov.br/documents/10181/3295768/%281%29RDC_53_2015_COMP.pdf/d38f507d-745c-46fb-a0a6-bd250f2e9892, accessed in July 2021.

27. Agência Nacional de Vigilância Sanitária (ANVISA); *Guia para Obtenção do Perfil de Degradação, e Identificação e Qualificação de Produtos de Degradação em Medicamentos*, Guia No. 04, 2015, https://storage.googleapis.com/wzukusers/user-21948565/documents/b42ac29ecf894ae08ab643c35a2eb2c1/Guia%20%20Perfis%20de%20Produtos%20de%20degrada%C3%A7%C3%A3o%20medicamentos.pdf, accessed in July 2021.

28. Bird, A. E. In *Analytical Profiles of Drug Substances and Excipients*, vol. 23, 1st ed.; Brittain, H. G., ed.; Academic Press: London, UK, 1994.

29. Gensmantel, N. P.; Proctor, P.; Page, M. I.; *J. Chem. Soc., Perkin Trans. 2* **1980**, *1725.*

30. Frańska, M.; *Ars Separacta Acta* **2012-2013**, 9-10, 25.

31. Thambavata, D.; Galappathy, P.; Mannaiperuma, U.; Jayakody, L.; Cristofoletti, R.; Abrahamsson, B.; Groot, D. W.; Langguth, P.; Mehta, M.; Parr, A.; Polli, J. E.; Shah, V. P.; Dressman, J.; *J. Pharm. Sci.* **2017**, *106*, 2930.

32. The United States Pharmacopoeia, USP 41, The United States Pharmacopoeial Convention: Rockville, 2018.

33. Felix, I. M. B.; Moreira, L. C.; Chiavone-Filho, U.; *Fluid Phase Equilib.* **2016**, *422*, 78.

34. Gállico, D. A.; Guerra, R. B.; Legendre, A. O.; Schnitzler, E.; Mendes, R. A.; Bannach, G.; *Braz. J. Therm. Anal.* **2013**, *2*, 45.

35. Han, J.; Suryanarayanan, R.; *Thermochim. Acta* **1999**, *329*, 163.

36. Carmo, A. C. M.; Piras, S. S.; Rocha, N. F. M.; Gratieri, T. H.; *BioMed Res. Int.* **2017**, ID 7894937.

37. Hickey, M. B.; Peterson, M. L.; Manas, E. S.; Alvarez, J.; Haefner, F.; Almarsson, O.; *J. Pharm. Sci.* **2007**, *96*, 1090.

38. Chen, J.; Sun, P.; Zhou, X.; Zhang, Y.; Huang, C.-H.; *Environ. Sci. Technol.* **2015**, *49*, 4218.

39. Li, M.; *Organic Chemistry of Drug Degradation*; RSC Publishing: Cambridge, UK, 2012.

40. Pharmaceutical Stress Testing: Predicting Drug Degradation, 2nd ed.; Baerstisch, S. W.; Ahsan, K. M.; Reed, R. A., eds.; Taylor & Francis: Boca Raton, USA, 2011.

Submitted: April 30, 2021
Published online: August 5, 2021